TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
about
CIViC databaseTreatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.Neutrophil-to-lymphocyte ratio after pazopanib treatment predicts response in patients with advanced soft-tissue sarcoma.Identifying actionable variants using next generation sequencing in patients with a historical diagnosis of undifferentiated pleomorphic sarcoma.A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas.Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas.Targeted next generation sequencing identified clinically actionable mutations in patients with esophageal sarcomatoid carcinoma.Analysis of Tissue and Circulating Tumor DNA by Next-Generation Sequencing of Hepatocellular Carcinoma: Implications for Targeted Therapeutics.Genomic landscape of advanced basal cell carcinoma: Implications for precision treatment with targeted and immune therapies.Apatinib-based targeted therapy against pulmonary sarcomatoid carcinoma: a case report and literature review
P2860
Q27612411-34EBC8D7-365E-4BB2-8A4D-33ABFCDCB4ECQ41105379-4C957AD2-1C29-464D-AD27-2C7075AD711DQ46296816-566513E6-3895-4086-9AC8-2C76FB6F76B0Q47685069-8E42F0DB-F8F4-4744-81D5-C49C26D2F6C1Q48005435-D8E92E52-5872-42CD-B8C3-E5560B58F38AQ49804873-E846CD60-738C-4369-9535-651077A69881Q49901846-4AC7ACC6-6625-42ED-9F01-7187B279A8F8Q52671439-EA0C0370-5039-486C-BFAC-820FDE69D510Q52673571-F6AC44D2-7302-4031-985E-5A4AC75C9DCDQ52684456-C702B65A-D7F8-41BC-B218-090426F92382Q52733765-65F457F0-42C3-4332-BFA0-3B65156CC2BDQ58739900-07D18FC9-0003-4B7E-A402-1AFF16109366
P2860
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@ast
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@en
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@nl
type
label
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@ast
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@en
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@nl
altLabel
TP53 mutational status is predictive of pazopanib response in advanced sarcomas
@en
prefLabel
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@ast
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@en
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@nl
P2093
P2860
P356
P1433
P1476
TP53 mutational status is predictive of pazopanib response in advanced sarcomas.
@en
P2093
P2860
P304
P356
10.1093/ANNONC/MDV598
P577
2016-03-01T00:00:00Z